V

Vir Biotechnology
D

VIR

10.160
USD
0.52
(5.34%)
Market Closed
Volume
110,764
EPS
0
Div Yield
0
P/E
-3
Market Cap
1,388,258,041
OverviewSignalsIdeasNews
Related Instruments
    AAPL
    -3.610
    (-1.63%)
    218.370 USD
    ABBV
    4.380
    (2.36%)
    189.700 USD
    AMZN
    -3.000
    (-1.60%)
    183.990 USD
    JNJ
    2.930
    (1.86%)
    160.770 USD
    MRNA
    -25.020
    (-20.99%)
    94.160 USD
    MSFT
    -1.14
    (-0.27%)
    417.07 USD
    N
    NVAX
    -0.250
    (-1.95%)
    12.560 USD
    PFE
    0.115
    (0.38%)
    30.650 USD
    PYPL
    -0.465
    (-0.71%)
    65.310 USD
    T
    TDOC
    -0.85000
    (-9.00%)
    8.59000 USD
News

Title: Vir Biotechnology

Sector: Healthcare
Industry: Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development,collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.